多发性骨髓瘤-话题@MedSci

#多发性骨髓瘤#

50篇内容 | 4446人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=964112, encodeId=e70e9641122a, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>多发性骨髓瘤与原发性淀粉样变性的区别, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=94, createdTime=2021-05-09, rootId=0, userName=hjhf, userId=88c54874945, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=953396, encodeId=0fb2953396f0, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Br J Cancer：ITGA6表达下调增强多发性骨髓瘤的侵袭作用并促进其发展为浆细胞白血病, objectType=article, longId=209342, objectId=a2c5209342f7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202142/1617293270011_2467676.PNG, objectUrl=/article/show_article.do?id=a2c5209342f7, replyNumber=0, likeNumber=163, createdTime=2021-04-02, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2c5209342f7, moduleTitle=Br J Cancer：ITGA6表达下调增强多发性骨髓瘤的侵袭作用并促进其发展为浆细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2c5209342f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=924004, encodeId=e12692400494, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>多发性骨髓瘤的治疗策略有待进一步研究。, objectTitle=多发性骨髓瘤, objectType=topic, longId=43116, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020121/1606821359582_4754896.jpg, objectUrl=null, replyNumber=0, likeNumber=117, createdTime=2021-02-10, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=918816, encodeId=988f91881603, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤, objectType=article, longId=206006, objectId=dea22060068e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021121/1611220870309_2110107.PNG, objectUrl=/article/show_article.do?id=dea22060068e, replyNumber=0, likeNumber=137, createdTime=2021-01-21, rootId=0, userName=zb1235672, userId=59321624668, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dea22060068e, moduleTitle=Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dea22060068e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=916410, encodeId=118891641093, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Plos Med：卡非佐米+来那度胺+地塞米松和环磷酰胺用作多发性骨髓瘤移植前诱导化疗的效果和安全性, objectType=article, longId=205699, objectId=a34920569953, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/192.jpg, objectUrl=/article/show_article.do?id=a34920569953, replyNumber=0, likeNumber=1, createdTime=2021-01-14, rootId=0, userName=zb1235672, userId=59321624668, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a34920569953, moduleTitle=Plos Med：卡非佐米+来那度胺+地塞米松和环磷酰胺用作多发性骨髓瘤移植前诱导化疗的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a34920569953)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=907272, encodeId=66e790e272ee, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Br J Cancer：逆转多发性骨髓瘤耐药性的替代策略, objectType=article, longId=204413, objectId=892c204413da, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20201211/1607657347001_2467676.PNG, objectUrl=/article/show_article.do?id=892c204413da, replyNumber=0, likeNumber=165, createdTime=2020-12-12, rootId=0, userName=Nebula-Qin, userId=74c72110107, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=892c204413da, moduleTitle=Br J Cancer：逆转多发性骨髓瘤耐药性的替代策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=892c204413da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=907086, encodeId=678b90e086ba, content=<a href='/topic/show?id=f7934849981' target=_blank style='color:#2F92EE;'>#帕比司他#</a>用于<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Lancet oncol：帕比司他联合皮下给予硼替佐米治疗复发性/难治性多发性骨髓瘤的疗效和安全性, objectType=article, longId=204420, objectId=fbc5204420da, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/rheumatoid_arthritis_s12_citrulline_test.jpg, objectUrl=/article/show_article.do?id=fbc5204420da, replyNumber=0, likeNumber=116, createdTime=2020-12-11, rootId=0, userName=lifefamily, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbc5204420da, moduleTitle=Lancet oncol：帕比司他联合皮下给予硼替佐米治疗复发性/难治性多发性骨髓瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbc5204420da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=905080, encodeId=d1aa90508001, content=<a href='/topic/show?id=21d764465c7' target=_blank style='color:#2F92EE;'>#沙利度胺#</a>及其衍生物已被广泛用于治疗恶性<a href='/topic/show?id=66c489335e5' target=_blank style='color:#2F92EE;'>#血液肿瘤#</a>和<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>，还用于很多实体瘤，如肝癌等，作为抗血管新生和免疫调节剂，作用不亚于贝伐单抗，对成人而言，安全性也是相当不错的。, objectTitle=沙利度胺可防止神经细胞死亡, objectType=article, longId=132282, objectId=ab43132282ae, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201803/20180313112158362.jpg, objectUrl=/article/show_article.do?id=ab43132282ae, replyNumber=0, likeNumber=205, createdTime=2020-12-05, rootId=0, userName=lifefamily, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab43132282ae, moduleTitle=沙利度胺可防止神经细胞死亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab43132282ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=881849, encodeId=27bb88184911, content=<a href='/topic/show?id=ff1c3654ebf' target=_blank style='color:#2F92EE;'>#卡非佐米#</a> 较 <a href='/topic/show?id=5ccae366556' target=_blank style='color:#2F92EE;'>#硼替佐米#</a>虽然是新一代药物，但是对于<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>而言，要比出差异并不容易。因此，大家不必过度迷信新药，老药在联合方案中，往往仍然是不错的。, objectTitle=Lancet oncol：卡非佐米 vs 硼替佐米联合来那度胺+地塞米松治疗多发性骨髓瘤的疗效, objectType=article, longId=200125, objectId=9b81200125b7, topicUrl=null, isHasObj=0, objectCover=, objectUrl=/article/show_article.do?id=9b81200125b7, replyNumber=0, likeNumber=197, createdTime=2020-09-01, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b81200125b7, moduleTitle=Lancet oncol：卡非佐米 vs 硼替佐米联合来那度胺+地塞米松治疗多发性骨髓瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b81200125b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=807334, encodeId=93b780e334ff, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>, objectTitle=Blood：卡非佐米-来那度胺-地塞米松联合干细胞移植治疗多发性骨髓瘤, objectType=article, longId=199134, objectId=f4861991340d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020810/1597030298455_2110107.PNG, objectUrl=/article/show_article.do?id=f4861991340d, replyNumber=0, likeNumber=171, createdTime=2020-08-10, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4861991340d, moduleTitle=Blood：卡非佐米-来那度胺-地塞米松联合干细胞移植治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4861991340d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=803190, encodeId=f6ba803190c5, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>延长生命相当厉害, objectTitle=Lancet：卡非佐米、达雷木单抗联合地塞米松治疗复发或难治性多发性骨髓瘤, objectType=article, longId=197722, objectId=54d019e7223c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020718/1595037872691_2051781.jpg, objectUrl=/article/show_article.do?id=54d019e7223c, replyNumber=0, likeNumber=152, createdTime=2020-07-18, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54d019e7223c, moduleTitle=Lancet：卡非佐米、达雷木单抗联合地塞米松治疗复发或难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54d019e7223c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=799947, encodeId=ed48e99947a0, content=<a href='/topic/show?id=dd85431162e' target=_blank style='color:#2F92EE;'>#多发性骨髓瘤#</a>mark, objectTitle=Blood：在多发性骨髓瘤中，单克隆免疫球蛋白促进骨丢失, objectType=article, longId=196564, objectId=f010196564d8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-is-checking-patient-x-ray-film-PY8MED5.jpg, objectUrl=/article/show_article.do?id=f010196564d8, replyNumber=0, likeNumber=159, createdTime=2020-06-26, rootId=0, userName=mswert122, userId=2a791737770, projectId=1, avatar=https://cdnapi.center.medsci.cn/medsci/head/2017/02/28/889a1910ded7780f3c049b354f1648b7.jpg, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f010196564d8, moduleTitle=Blood：在多发性骨髓瘤中，单克隆免疫球蛋白促进骨丢失, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f010196564d8)], followStatus=false, userIsMember=true, type=1, lengthMark=0)] 梅斯话题小助手

多发性骨髓瘤

2020-05-29

hjhf (审核中...)

前往app查看评论内容

#多发性骨髓瘤#多发性骨髓瘤与原发性淀粉样变性的区别

2021-05-09

智者为医08 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

Br J Cancer：ITGA6表达下调增强多发性骨髓瘤的侵袭作用并促进其发展为浆细胞白血病

2021-04-02

yangchou (审核中...)

前往app查看评论内容

#多发性骨髓瘤#多发性骨髓瘤的治疗策略有待进一步研究。

2021-02-10

zb1235672 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

Lancet Haematol：来那度胺-硼替佐米-地塞米松±Elotuzumab治疗高危型多发性骨髓瘤

2021-01-21

zb1235672 (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

Plos Med：卡非佐米+来那度胺+地塞米松和环磷酰胺用作多发性骨髓瘤移植前诱导化疗的效果和安全性

2021-01-14

Nebula-Qin (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

Br J Cancer：逆转多发性骨髓瘤耐药性的替代策略

2020-12-12

lifefamily (审核中...)

前往app查看评论内容

#帕比司他#用于#多发性骨髓瘤#

Lancet oncol：帕比司他联合皮下给予硼替佐米治疗复发性/难治性多发性骨髓瘤的疗效和安全性

2020-12-11

lifefamily (审核中...)

前往app查看评论内容

#沙利度胺#及其衍生物已被广泛用于治疗恶性#血液肿瘤#和#多发性骨髓瘤#，还用于很多实体瘤，如肝癌等，作为抗血管新生和免疫调节剂，作用不亚于贝伐单抗，对成人而言，安全性也是相当不错的。

沙利度胺可防止神经细胞死亡

2020-12-05

lovetcm (审核中...)

前往app查看评论内容

#卡非佐米# 较 #硼替佐米#虽然是新一代药物，但是对于#多发性骨髓瘤#而言，要比出差异并不容易。因此，大家不必过度迷信新药，老药在联合方案中，往往仍然是不错的。

Lancet oncol：卡非佐米 vs 硼替佐米联合来那度胺+地塞米松治疗多发性骨髓瘤的疗效

2020-09-01

lovetcm (审核中...)

前往app查看评论内容

#多发性骨髓瘤#

Blood：卡非佐米-来那度胺-地塞米松联合干细胞移植治疗多发性骨髓瘤

2020-08-10

lovetcm (审核中...)

前往app查看评论内容

#多发性骨髓瘤#延长生命相当厉害

Lancet：卡非佐米、达雷木单抗联合地塞米松治疗复发或难治性多发性骨髓瘤

2020-07-18

(审核中...)

前往app查看评论内容

#多发性骨髓瘤#mark

Blood：在多发性骨髓瘤中，单克隆免疫球蛋白促进骨丢失

2020-06-26

科室
- - 订阅+
  - 更多科室
工具
服务